Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsVanita R. Aroda, Ildiko Lingvay, Vincent Woo et al.|Diabetes & Metabolism|2019Cited by 281